Synaptic plasticity

Aptinyx to Report First Quarter 2021 Financial Results on Thursday, May 13, 2021

Retrieved on: 
Thursday, April 29, 2021
Biotechnology, Nanotechnology, Pharmaceutical, Health, Medical devices, Technology, Clinical trials, Other Health, Branches of biology, Biology, Neuroscience, Neural circuits, Neurophysiology, Neuroplasticity, Neurology, Glutamate, NMDA receptor, Neuron, Synaptic plasticity

ET to report first quarter 2021 financial results and discuss recent business highlights.\nTo access the live conference call, please dial (833) 772-0394 (domestic) or (236) 738-2205 (international) and refer to conference ID 3628539.

Key Points: 
  • ET to report first quarter 2021 financial results and discuss recent business highlights.\nTo access the live conference call, please dial (833) 772-0394 (domestic) or (236) 738-2205 (international) and refer to conference ID 3628539.
  • A live audio webcast of the event will be available on the Investors & Media section of Aptinyx\xe2\x80\x99s website at https://ir.aptinyx.com .
  • Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate\xe2\x80\x94rather than block or over-activate\xe2\x80\x94NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication.
  • The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment.

Aptinyx to Participate in Upcoming Conferences

Retrieved on: 
Tuesday, April 27, 2021
Mental health, Health, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Branches of biology, Biology, Neuroscience, Neural circuits, Glutamate, Neurophysiology, Neuroplasticity, Ionotropic glutamate receptors, NMDA receptor, Nervous system, Synaptic plasticity

ET on April 29, 2021; and\n7th Annual Truist Securities Life Sciences Summit \xe2\x80\x93 Aptinyx management will participate in one-on-one meetings with investors throughout the conference on May 4 \xe2\x80\x93 5, 2021.\nAptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders.

Key Points: 
  • ET on April 29, 2021; and\n7th Annual Truist Securities Life Sciences Summit \xe2\x80\x93 Aptinyx management will participate in one-on-one meetings with investors throughout the conference on May 4 \xe2\x80\x93 5, 2021.\nAptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders.
  • Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate\xe2\x80\x94rather than block or over-activate\xe2\x80\x94NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication.
  • The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment.
  • Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders.

Aptinyx to Participate in Upcoming Investor Conferences

Retrieved on: 
Monday, February 22, 2021
Research, FDA, Clinical trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Branches of biology, Biology, Neuroplasticity, Glutamate, Molecular neuroscience, Cell signaling, NMDA receptor, Synaptic plasticity, Brain-derived neurotrophic factor

Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders.

Key Points: 
  • Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders.
  • Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulaterather than block or over-activateNMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication.
  • The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment associated with Parkinsons disease.
  • Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders.

Aptinyx to Present at Upcoming Investor Conferences

Retrieved on: 
Wednesday, February 19, 2020
Branches of biology, Neuroscience, Biology, Neural circuits, Neuroplasticity, Neurophysiology, Neurology, Cell signaling, NMDA receptor, Synaptic plasticity, Nervous system

A replay of the webcast will be archived on Aptinyxs website for 30 days following the event.

Key Points: 
  • A replay of the webcast will be archived on Aptinyxs website for 30 days following the event.
  • Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders.
  • Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulaterather than block or over-activateNMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication.
  • Aptinyx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Aptinyx to Present at Upcoming Investor Conferences

Retrieved on: 
Thursday, November 14, 2019
Branches of biology, Neuroscience, Biology, Neural circuits, Neurophysiology, Neurology, Cell signaling, NMDA receptor, Synaptic plasticity, Neuroplasticity, Nervous system

A replay of the webcast will be archived on Aptinyxs website for 30 days following the event.

Key Points: 
  • A replay of the webcast will be archived on Aptinyxs website for 30 days following the event.
  • Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders.
  • Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulaterather than block or over-activateNMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication.
  • Aptinyx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Beckman Foundation Names Mark Bear, Ph.D., of the Massachusetts Institute of Technology as 2018 Beckman-Argyros Vision Research Award Winner

Retrieved on: 
Tuesday, August 7, 2018
Neuroscience, Nervous system, Neuroplasticity, RTT, Neurophysiology, Neural networks, Biology, Amblyopia, Mark Bear, Synaptic plasticity, Arnold Orville Beckman, Beckman

IRVINE, Calif., Aug. 7, 2018 /PRNewswire-PRWeb/ -- The Arnold and Mabel Beckman Foundation today announced its 2018 Beckman-Argyros Vision Research Award winner is Dr. Mark Bear, Picower Professor of Neuroscience at the Massachusetts Institute of Technology.

Key Points: 
  • IRVINE, Calif., Aug. 7, 2018 /PRNewswire-PRWeb/ -- The Arnold and Mabel Beckman Foundation today announced its 2018 Beckman-Argyros Vision Research Award winner is Dr. Mark Bear, Picower Professor of Neuroscience at the Massachusetts Institute of Technology.
  • Bear and MIT will receive $100,000 and $400,000, respectively, to further advance his research harnessing synaptic plasticity to promote recovery from amblyopia, commonly known as "lazy eye."
  • Through this research, they uncovered the synaptic basis of amblyopia, a severe visual impairment caused by poor quality vision during infancy and early childhood.
  • Instead, their findings indicate that vision loss is actively triggered by neural activity originating in the affected eye.